These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 28653570)

  • 1. The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives.
    Kourie HR; Awada G; Awada A
    Immunotherapy; 2017 Jun; 9(8):647-657. PubMed ID: 28653570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Learning from the "tsunami" of immune checkpoint inhibitors in 2015.
    Kourie HR; Awada G; Awada AH
    Crit Rev Oncol Hematol; 2016 May; 101():213-20. PubMed ID: 27051042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives].
    Kfoury M; Disdero V; Vicier C; Le Saux O; Gougis P; Sajous C; Vignot S
    Bull Cancer; 2018; 105(7-8):686-695. PubMed ID: 29933886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasculitis associated with immune checkpoint inhibitors-a systematic review.
    Daxini A; Cronin K; Sreih AG
    Clin Rheumatol; 2018 Sep; 37(9):2579-2584. PubMed ID: 29923081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
    Moon EK; Langer CJ; Albelda SM
    Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
    Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
    Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
    Chang X; Lu X; Guo J; Teng GJ
    Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Side-effects of checkpoint inhibitor-based combination therapy.
    Kourie HR; Klastersky JA
    Curr Opin Oncol; 2016 Jul; 28(4):306-13. PubMed ID: 27136134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
    Chen PL; Roh W; Reuben A; Cooper ZA; Spencer CN; Prieto PA; Miller JP; Bassett RL; Gopalakrishnan V; Wani K; De Macedo MP; Austin-Breneman JL; Jiang H; Chang Q; Reddy SM; Chen WS; Tetzlaff MT; Broaddus RJ; Davies MA; Gershenwald JE; Haydu L; Lazar AJ; Patel SP; Hwu P; Hwu WJ; Diab A; Glitza IC; Woodman SE; Vence LM; Wistuba II; Amaria RN; Kwong LN; Prieto V; Davis RE; Ma W; Overwijk WW; Sharpe AH; Hu J; Futreal PA; Blando J; Sharma P; Allison JP; Chin L; Wargo JA
    Cancer Discov; 2016 Aug; 6(8):827-37. PubMed ID: 27301722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Not Available].
    Reverdy T; Gau M; Karabajakian A; Neidhardt EM; Fayette J
    Bull Cancer; 2018 Dec; 105 Suppl 1():S35-S42. PubMed ID: 30595197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application.
    Tray N; Weber JS; Adams S
    Cancer Immunol Res; 2018 Oct; 6(10):1122-1128. PubMed ID: 30279188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
    Farina MS; Lundgren KT; Bellmunt J
    Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.
    Davis AA; Patel VG
    J Immunother Cancer; 2019 Oct; 7(1):278. PubMed ID: 31655605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
    Hu ZI; Ho AY; McArthur HL
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring immune-checkpoint blockade: response evaluation and biomarker development.
    Nishino M; Ramaiya NH; Hatabu H; Hodi FS
    Nat Rev Clin Oncol; 2017 Nov; 14(11):655-668. PubMed ID: 28653677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next generation predictive biomarkers for immune checkpoint inhibition.
    Khagi Y; Kurzrock R; Patel SP
    Cancer Metastasis Rev; 2017 Mar; 36(1):179-190. PubMed ID: 27873079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advances in immune checkpoint inhibitors in gastrointestinal cancer].
    Zhu XR; Zheng LZ
    Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):646-649. PubMed ID: 28926891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics.
    Twomey JD; Zhang B
    AAPS J; 2021 Mar; 23(2):39. PubMed ID: 33677681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities.
    Cousin S; Italiano A
    Clin Cancer Res; 2016 Sep; 22(18):4550-5. PubMed ID: 27435397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.